ICON Public (NASDAQ:ICLR) Updates FY 2024 Earnings Guidance

ICON Public (NASDAQ:ICLR) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share guidance of 13.900-14.100 for the period, compared to the consensus earnings per share estimate of 13.970. The company issued revenue guidance of $8.3 billion-$8.3 billion, compared to the consensus revenue estimate of $8.3 billion. ICON Public also updated its FY 2025 guidance to 13.000-15.000 EPS.

ICON Public Stock Performance

ICON Public stock opened at $217.99 on Tuesday. The company has a market cap of $17.98 billion, a PE ratio of 24.30, a PEG ratio of 1.54 and a beta of 1.20. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. ICON Public has a 1 year low of $183.38 and a 1 year high of $347.72. The company’s 50-day moving average is $211.31 and its two-hundred day moving average is $270.81.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The company had revenue of $2.03 billion for the quarter, compared to analyst estimates of $2.13 billion. During the same period last year, the firm earned $3.10 earnings per share. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. Equities analysts anticipate that ICON Public will post 13.42 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on ICLR shares. Leerink Partnrs raised shares of ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. Citigroup dropped their price objective on ICON Public from $300.00 to $290.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Royal Bank of Canada started coverage on ICON Public in a research note on Tuesday, January 7th. They issued an “outperform” rating and a $263.00 target price for the company. Leerink Partners reaffirmed an “outperform” rating and set a $255.00 price target (down previously from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Finally, Robert W. Baird cut their price objective on ICON Public from $249.00 to $225.00 and set a “neutral” rating on the stock in a report on Wednesday, November 20th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, ICON Public currently has a consensus rating of “Moderate Buy” and an average price target of $287.00.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.